SHANGHAI – Hua Medicine Ltd.'s sinogliatin, a fourth-generation glucokinase activator (GKA), looks set to prove it has overcome the issues of past GKAs to provide 24-hour glucose control in diabetics with the potential to improve pancreatic beta cell function.